In multiple sclerosis (MS), mindfulness may increase the time a patient spends asleep while in bed, but physical activity appears to have small and inconsistent benefits on sleep. That’s according to a meta-analysis of five published studies that looked at the impact of interventions designed to improve sleep among people with MS. “Objective improvements in…
The ins, outs, ups, and downs of choosing an MS-accessible minivan
I would say that no one grows up telling themselves that they can’t wait to get their first minivan, but that’s probably just my opinion. I will allow for the possibility that some people have thought that exact thing, but I never did. As I imagine is the case for most people, I didn’t learn…
Developer creates under-the-tongue cladribine for testing in MS
A new formulation — a film that dissolves under the tongue — of cladribine for treating multiple sclerosis (MS) has moved closer to clinical testing, according to an update from its developer. Bionxt Solutions announced that it has completed manufacturing of a clinical-grade batch of BNT23001, its sublingual, or under-the-tongue, formulation of cladribine. The batch…
MS drugs in the media
Tweet News Multiple sclerosis: Could Roche’s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS? BMJ 2026; 393 doi: https://doi.org/10.1136/bmj.s666 (15 April 2026) Cite this as: BMJ 2026;393:s666 Neurological drugs have been in the media over the last couple of days. There is a report that Alzheimer drugs are not good enough and it has been…
Meeting Abstracts are they a load of old biased cobblers?
Tweet This paper is perhaps interesting as we go into AAN week…All that will surface for the masses is the Conference abstract. For AAN they will all be published in the Journal Neurology, just as ECTRIMS abstracts are published in the Multiple Sclerosis Journal. The question here is whether abstracts published in meetings are biased…
MS treatment during pregnancy found safe for babies’ brain growth
Using disease-modifying treatments shortly prior to or during pregnancy does not seem to increase the risk of neurodevelopmental disorders in exposed children, according to a real-world study of mothers with multiple sclerosis (MS). Still, sphingosine-1-phosphate (S1P) receptor modulators, which include therapies such as Gilenya (fingolimod), Mayzent (siponimod), and Ponvory (ponesimod), were linked to an increased…
A springtime downpour brings back memories of my biggest supporter
As I write this, the April showers that bring May flowers have brought forth a string of gloomy days here in central Texas. During days like these, I cannot help but be reminded of my grandma, who passed away about a year ago after a battle with dementia. I remember my childhood spent in her…
Well Well Wellness
By Angel Blair When it comes to wellness and how we take care of our minds and bodies, there’s definitely some leeway as to what works for each person and what type of wellness is being referred to. If we’re … Continue reading → Source: blog.mymsaa.org
New blood test may help track MS disease between relapses
A blood test being developed by Roche to measure a marker of nerve cell damage has received CE mark approval for the detection of neuroinflammation in people with relapsing-remitting multiple sclerosis (RRMS). Called Elecsys Neurofilament Light Chain (NfL), the test is designed to measure NfL levels, which are increased in many neurological conditions due to…
Counting cell in blood as a predicitve factor for disease activity
Tweet This paper argues that if you look at blood cell counts it may help about look at disease activity. This view is perhaps abit controversial as there have been many studies looking at immune cell subsets circulating in the blood after a DMT and have not been able to find an association with disease…